See why infusion centers prefer Mandolin over Tennr

Mandolin offers end-to-end AI automation of the entire specialty medication lifecycle — from referral to reimbursement — without integrations, handoffs, or hidden bottlenecks.

Built for speed, accuracy, and margin, our platform handles every workflow nuance that document-only solutions leave behind.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Our results speak for themselves

Mandolin helps infusion centers accelerate authorizations, reduce denials, and unlock more revenue — all without adding staff. Explore real-world case studies showing how clinics are scaling profitably while improving patient access and experience.

24x
increase in speed
Previously, staff processed an average of 250 documents per day manually, with each document taking 20 minutes and up to 3 days to make it into the EHR. With Mandolin’s AI agents, that same workflow now takes just 3 minutes per document, with end-to-end turnaround under 2 hours — a 24x improvement in speed. What once required over 100 full-time staff has become a streamlined, automated process, enabling faster patient starts and a more efficient back office.
CEO
CEO, national AIC company
0
day backlog
Mandolin eliminated a 4-day prescription backlog by automating intake workflows that previously relied on 2–3 full-time staff. Before go-live, the team processed 200–300 new prescriptions per day manually, spending 10–12 minutes per Rx and struggling to stay ahead. Now, the backlog is zero, and prescriptions are processed in real time — accelerating patient access and freeing up staff to focus on higher-value clinical tasks.
SVP of Operations
SVP of Operations, top 20 specialty pharmacy
13
Outsourced FTEs
Mandolin’s automation enabled a national AIC to scale to 4,500+ patients/month while refocusing 13 outsourced roles on complex cases instead of repetitive task. By replacing fragmented, labor-intensive workflows with AI agents, they streamlined operations, reduced overhead, and accelerated time to therapy — all without increasing headcount.
Director of FP&A
Director of FP&A, national AIC company